PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer
Expert Opin Biol Ther
.
2020 Sep;20(9):965-970.
doi: 10.1080/14712598.2020.1786531.
Epub 2020 Jun 28.
Authors
Daniel Larcombe-Young
1
,
Sophie Papa
2
3
,
John Maher
1
4
5
6
Affiliations
1
King's College London , School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London, UK.
2
King's College London , School of Cancer and Pharmaceutical Sciences, ImmunoEngineering Group, Guy's Cancer Centre, Great Maze Pond, London, UK.
3
Depart of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond , London, UK.
4
Leucid Bio Ltd., Guy's Hospital, Great Maze Pond , London, UK.
5
Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust , London UK.
6
Department of Immunology, Eastbourne Hospital , Eastbourne, UK.
PMID:
32567382
DOI:
10.1080/14712598.2020.1786531
No abstract available
Keywords:
Chimeric antigen receptor; erbb; head and neck cancer; t4 immunotherapy.
Publication types
Editorial
Research Support, Non-U.S. Gov't